Jin Lee

Jin Lee

Auto-generated profile, based on publicly available information

Jin Lee

Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2020 in World Journal of Gastrointestinal Pharmacology and Therapeutics
Verified
Journal Article
Open access
SJSu Jin Jeong
Su Jin Jeong
JLJin Lee
Jin Lee
Management of gastric outlet obstruction: Focusing on endoscopic approach

19 August 2022 in Medicine
Verified
Journal Article
Open access
SKSu Jin Kim
Su Jin Kim
SJSam Ryong Jee
Sam Ryong Jee
MPMoo In Park
Moo In Park
KJKyoungwon Jung
Kyoungwon Jung
Gwang Ha KimGwang Ha Kim
Gwang Ha Kim
MKMyeongseok Koh
Myeongseok Koh
Background: Increasing clarithromycin resistance has led to changes in several guidelines for treatment of Helicobacter pylori infections. We compared the H. pylori eradication rates of the empirical concomitant therapy (CoT) and a tailored therapy (TaT) using dual-priming oligonucleotide-based polymerase chain reaction to detect mutations in the 23S rRNA gene that are related to clarithromycin resistance. Methods: Between June 2020 and May 2021, 290 patients were enrolled and randomly assigned to 2 groups. In the CoT group, the patients received rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 14 days. In the TaT group, point mutation-negative patients received rabeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 14 days and point mutation-positive patients received rabeprazole 20 mg twice daily, metronidazole 500 mg thrice daily, and bismuth 120 mg and tetracycline 500 mg 4 times daily for 14 days. Results: A total of 290 and 261 patients were included in the intention-to-treat (ITT) and per-protocol (PP) analyses, respectively. A2142G and/or A2143G point mutations were identified in 28.6% of the patients. No significant difference in eradication rates were observed between the 2 groups as per ITT (CoT, 82.8% and TaT, 85.5%, P = .520) and PP (CoT, 88.6% and TaT, 94.6%, P = .084) analyses. In point mutation-positive patients, the eradication rates in the CoT group were lower than those in the TaT group as per ITT (69.8% and 87.5%, respectively, P = .050) and PP (76.9% and 97.1%, respectively, P = .011) analyses. Conclusion: CoT and TaT showed similar overall eradication rates for H. pylori. However, CoT eradication rate was suboptimal, especially in point mutation-positive patients.

8 April 2009 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
KYKeisuke Yoshida
Keisuke Yoshida
Akiko SuzukiAkiko Suzuki
Akiko Suzuki
TNToshiyuki Nagashima
Toshiyuki Nagashima
JLJin Lee
Jin Lee
CHChoichi Horiuchi
Choichi Horiuchi
TITomio Inoue
Tomio Inoue

8 May 2024 in Helicobacter
Verified
Journal Article
Open access
KJKyoungwon Jung
Kyoungwon Jung
SJSam Ryong Jee
Sam Ryong Jee
MLMoon Won Lee
Moon Won Lee
MKMyeongseok Koh
Myeongseok Koh
SKSu Jin Kim
Su Jin Kim
MPMoo In Park
Moo In Park
Background: Recently, a simple tailored therapy based on clarithromycin resistance has been implemented as Helicobacter pylori (H. pylori) eradication therapy. Nonetheless, despite the tailored therapy and frequent adverse events, studies on treatment period are lacking. This study aimed to compare the H. pylori eradication rates of 7‐day and 14‐day tailored therapy regimens according to clarithromycin resistance.Materials and Methods: This multicenter, prospective, randomized, noninferiority trial enrolled H. pylori‐positive patients who were randomly assigned to 7‐day and 14‐day regimen groups, depending on the presence or absence of clarithromycin resistance by 23S rRNA gene point mutations. Standard triple therapy (STT) (20 mg rabeprazole, 1 g amoxicillin, and 500 mg clarithromycin twice daily) or bismuth quadruple therapy (BQT) (20 mg rabeprazole twice daily, 500 mg metronidazole thrice daily, 120 mg bismuth four times daily, and 500 mg tetracycline four times daily) was assigned by clarithromycin resistance. Eradication rates and adverse events were evaluated.Results: A total of 314 and 278 patients were included in the intention‐to‐treat (ITT) and per‐protocol (PP) analyses, respectively; however, 31 patients were lost to follow‐up, whereas five patients violated the protocol. Both the 7‐day and 14‐day regimens showed similar eradication rates in the ITT (7‐day vs. 14‐day: 78.3% vs. 78.3%, p > 0.99) and PP (87.9% vs. 89.1%, p = 0.851) analyses. Non‐inferiority was confirmed (p < 0.025). A subgroup analysis according to clarithromycin resistance (clarithromycin resistance rate: 28.7%) revealed no significant difference in eradication rates between the 7‐day and 14‐day STT (90.0% vs. 90.1%, p > 0.99) and BQT (82.5% vs. 86.5%, p = 0.757). Furthermore, adverse events did not significantly differ between the two groups.Conclusions: The 7‐day triple and quadruple therapy according to clarithromycin resistance showed similar eradication rates, as compared to the 14‐day therapy.

1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JKJae Hoon Kim
Jae Hoon Kim
JNJi Eun Na
Ji Eun Na
JLJeonghwan Lee
Jeonghwan Lee
YPYong Eun Park
Yong Eun Park
JLJin Lee
Jin Lee
SPSeung Ha Park
Seung Ha Park
Kim JH, et al. J Korean Med Sci. 2023 Dec;38:e412. https://doi.org/10.3346/jkms.2023.38.e412

25 July 2020 in The Korean Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
HJHee Soo Jung
Hee Soo Jung
JLJin Lee
Jin Lee
KNKyung Han Nam
Kyung Han Nam
SJSu Jin Jeong
Su Jin Jeong
EOEun Hye Oh
Eun Hye Oh
TKTae Oh Kim
Tae Oh Kim
Hee Soo Jung, Jin Lee, Kyung Han Nam, Su Jin Jeong, Eun Hye Oh, Yong Eun Park, Jongha Park and Tae Oh Kim. Korean J Gastroenterol 2020;76:37-41. https://doi.org/10.4166/kjg.2020.76.1.37